TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Levels of pro-inflammatory and anti-inflammatory lipid mediators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Fear of Recurrence Level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of surgical conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reliability of information retrieval method
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventilatory changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Complete Tumor Regression Rate (TRG1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: T-cell status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Participation in breast cancer screening program
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Patients Reported With Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Stool Form
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Spermatomcyte count in the ejaculate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of solicited symptoms of grade 3 intensity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Overall Psychological Functioning (OQ-45)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Center for Epidemiologic Studies Depression (CES-D) scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Causes of death
Endpoint domain: Mortality/survival
Primary endpoint: Change in Reflux Disease Questionnaire Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of test positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of the positive result of the test with the manifestations of the signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of COVID
Endpoint domain: Mortality/survival
Primary endpoint: Vancouver Scar Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Prostate Specific Antigen (PSA) Progression Free Rate at 4 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy (Sensitivity and Specificity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Clinically Relevant Treatment Emergent ECG Changes
Endpoint domain: Adverse events/effects
Primary endpoint: Time to reach protective anti-HAV levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective response rate (Confirmed Complete Remission + Confirmed Partial Remission)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number and severity of treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Liver function recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: chest x-ray
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: lung ultrasonography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Unified Parkinson's Disease Rating Scale Subscale II Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unified Parkinson's Disease Rating Scale Subscale III Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Hoehn and Yahr Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 Hour Opioid Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycemic load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Arterial stiffness (assessed by pulse wave velocity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the plasma drug concentration versus time curve from 0 to 24 hours (AUC[0-24])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Injection Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Day 90 modified Rankin scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: number of patients achieving complete remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability as measured by dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of identifying candidate tumor-specific neoantigens
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Feasibility of manufacturing a neoantigen-based DNA vaccine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Feasibility of administering the vaccine to a patient
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in psychosocial health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in physician-patient communication
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Amount of unchanged ipratropium excreted in the urine from 0 to 24 h after a single dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Amount of unchanged ipratropium excreted in the urine within 1 hour at steady state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Amount of unchanged ipratropium excreted in the urine over the 6 h dosing interval at steady state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Breath hydrogen response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Subjects With Any Solicited Local and Systemic Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Any Serious Adverse Events (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Study Withdrawal, New Onset of Chronic Disease (NOCDs) and Adverse Events of Special Interest (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Human Complement Serum Bactericidal Assay (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup C (MenC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lysis of blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 24-hour profiles and AUCs of hormones influencing appetite and weight regulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: In-hospital MACE
Endpoint domain: Adverse events/effects
Primary endpoint: NRS score of neck and shoulder pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: cerebral connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: microglia activation patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: blood-based biomarkers for differentiation of AD, SCI and CBS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to Corticosteroid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cognitive dysfunction
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Spontaneous pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence/incidence of urinary symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of abnormal results of Physical examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of abnormal Vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of abnormal results of Laboratory tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients receiving all planned chemotherapeutic cycles
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Apparent diffusion coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal pain perceived during lumbar puncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pathologic Complete Response (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: CTC Enumeration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in ADAS-Cog Total Score at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline in CDR-SB Score at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Participant BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Who Completed the 14-day Double-blind Phase
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Gastroparesis Cardinal Symptom Index (GSCI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Residual plasma concentrations of amoxicillin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of moderate or severe diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Change in number of health behavior risks
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in number of minutes spent on stress management
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in number of servings of fruits and vegetables consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PTSD symptom severity (CAPS-5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in peak fear
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in approach level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Behavioral Indicators of Infant Pain (BIIP) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in circulating levels of sex steroid hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence and severity of cell therapy-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Motor-evoked potentials/motor action potential amplitude ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline jump height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Incidence of Corneal Inflammatory Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: incidence of anterior knee pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Visual analogue scale for anterior knee pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percent of Subjects Requiring Rescue Midazolam for Sedation
Endpoint domain: Adverse events/effects
Primary endpoint: HbA1C (Glycated Haemoglobin) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to insertion of CVC into a subclavian vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Wechsler Pre-school and Primary Scale of Intelligence -IV
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Composite facial score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphology of meibomian glands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional feature of meibomian glands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change in MADRS Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of patients with COVID-19 positive samples/biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of emboli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postprandial whole blood glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of device or procedure related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Phleum Pratense Specific Immunoglobulin G4 (IgG4) in Serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: incidence of DLTs
Endpoint domain: Adverse events/effects
Primary endpoint: Overall survival analysis
Endpoint domain: Mortality/survival
Primary endpoint: Facial Acne Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of CD8 T cells specific for vaccinated APVAC peptides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Inflammatory monocyte-associated biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of Subjects Achieving a Reduction of at Least 25% of the Volume of the Rectum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prescription frequency of potentially inappropriate medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent Change in Left Ventricular End Systolic Volume (LVESV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in WJ-III Basic Reading Standard Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Grade Point Average (GPA)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: All cause mortality rates
Endpoint domain: Mortality/survival
Primary endpoint: Global perception of improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: lung lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Brain area activity in arithmetic processing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Average Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ongoing pregnancy beyond 20th gestational week
Endpoint domain: Mortality/survival
Primary endpoint: Rate of Local Control in the Globe at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum postoperative weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Defecation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Retentive Fecal Incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Overall Clinical Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complementary Deoxyribonucleic Acid (cDNA) Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response Signature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Unique Activity lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Wart Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in blanching
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Functional Movement Screen Assessment (FMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Equivalence of Images from Rest Rubidium-82 Perfusion PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Achieving ACR20 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in pain expectation rating score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain rating score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain unpleasantness rating score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positional Stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Rating Scale for Depression (HDRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression - Severity (CGI-S)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pharmacokinetics of elacytarabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Measure of glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Satisfaction with Care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adherence to the diabetes self-management regimen
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: metabolic bone markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: IBS Severity Scoring System (IBS-SSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Dose-Limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: High sensitive C reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Amylase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Lipase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anxiety questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mood scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: attention bias scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of days until recovery of bowel movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of patients reaching 28 days of postexposure prophylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Patients With Evaluable CT Scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of HIV/HTN patients with HTN Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of HIV/HTN patients with HIV/HTN Dual Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of seasonal influenza vaccination sets released
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Daily physical activity energy expenditure (PAEE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: glucose homeostasis levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: blood biochemistry indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence and amount of inflammatory cells and bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: DNA methylation characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erythrocyte Glutamine/Glutamate Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of women reporting availability of LARC methods at uterine evacuation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Receiving Rehabilitation Services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Home-time
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Reduction in Total CHO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in LDH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of clinical postoperative pancreatic fistula (POPF) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Knee injury and Osteoarthritis Outcome Score-12 (KOOS-12)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning